# US Patent 8,168,775: TTR-Targeting siRNA Claims, Scope, Expiration Risk and Competitive Landscape

US Patent 8,168,775 covers specific double-stranded RNA molecules that inhibit transthyretin, or TTR, expression. Its core protection is sequence-specific: the antisense strand must contain SEQ ID NO:170, and the RNA duplex must have strands of 19 to 24 nucleotides. Dependent claims extend protection to identified strand pairs, defined TTR mRNA binding and cleavage sites, chemical modifications, ligand conjugates, cells, vectors, pharmaceutical compositions, and cell-based methods.

The patent is most relevant to RNAi products directed at hepatic TTR, including patisiran and related development programs. Its strongest claims are the sequence-specific composition claims. Its broader platform claims are narrower in practical effect because they remain tied to the required antisense sequence.

What does US Patent 8,168,775 protect?

The patent protects a TTR-specific dsRNA architecture rather than every TTR inhibitor.

Claim 1 requires all of the following:

A double-stranded RNA.
A sense strand and an antisense strand.
An antisense region complementary to TTR mRNA.
A 19-nucleotide region of complementarity.
An antisense strand comprising SEQ ID NO:170.
Strand lengths of 19, 20, 21, 22, 23, or 24 nucleotides.

The sequence limitation is decisive. A competing molecule that inhibits TTR through a different antisense sequence would not literally satisfy claim 1, even if it has the same therapeutic target, strand length, delivery system, or mechanism of action.

The patent therefore has a layered claim structure:

Claim group	Claims	Protected subject matter
Core dsRNA	1	TTR-targeting dsRNA containing antisense SEQ ID NO:170
Specific duplexes	2-4	Three enumerated sense/antisense sequence pairs
Target region	5, 9, 16	SEQ ID NO:169 and TTR mRNA positions 628-646
Cleavage profile	7-8	Cleavage or non-cleavage at positions 636-638
Chemical modifications	10-13	2'-O-methyl, 2'-fluoro, phosphorothioate and related modifications
Conjugates	14	Ligand-conjugated dsRNA
Functional potency	15	Approximately 95% TTR mRNA inhibition at 10 nM in HepG2 or Hep3B cells
Biological materials	17-19	Cells and vectors containing the dsRNA
Pharmaceutical compositions	20, 22	TTR-inhibiting compositions
Methods	21, 23	Cell-contacting methods that degrade TTR mRNA

How narrow is independent claim 1?

Claim 1 is a sequence-defined composition claim with a limited length range. It is narrower than a generic claim to any TTR-directed siRNA, but broader than claims limited to one exact duplex.

The phrase "comprising SEQ ID NO:170" potentially permits additional nucleotides outside the recited antisense sequence, subject to the claim's 19-nucleotide complementary-region and strand-length limitations. The exact construction depends on how the sequence identifiers and surrounding prosecution history are interpreted.

The claim does not require:

a particular delivery vehicle;
a particular chemical modification;
a particular administration route;
a particular dose;
a particular disease indication;
a particular patient population;
a particular lipid nanoparticle composition;
a particular level of serum TTR reduction; or
in vivo administration.

This makes claim 1 potentially relevant to naked RNA, lipid-formulated RNA, conjugated RNA, and research-use compositions if the accused product contains the required sequence and strand architecture.

The claim also does not require the dsRNA to cleave TTR mRNA at a specific position. Claims 7 and 8 separately address cleavage behavior.

Which sequence-specific TTR duplexes are claimed?

Claims 2, 3, and 4 depend on claim 1 and identify exact strand pairs:

Claim	Sense strand	Antisense strand	Practical effect
2	SEQ ID NO:449	SEQ ID NO:450	Exact duplex limitation
3	SEQ ID NO:729	SEQ ID NO:730	Exact duplex limitation
4	SEQ ID NO:1009	SEQ ID NO:1010	Exact duplex limitation

Claims 2-4 are narrower than claim 1 because each requires a specified sense strand and antisense strand. They may be easier to test for literal infringement through sequence alignment, but they are more vulnerable to design-around strategies using altered guide sequences or changed strand architecture.

Claims 22 and 23 specifically depend on the dsRNA of claim 4. They protect pharmaceutical compositions and cell-based TTR inhibition methods using that exact duplex.

What TTR mRNA region does the patent cover?

Claims 5, 9, and 16 define a target region centered on positions 628 through 646 of SEQ ID NO:1331.

Claim 9 states that the dsRNA anneals to TTR mRNA between guanine 628 and uracil 646. That is a 19-nucleotide target interval. Claim 16 separately requires antisense base pairing with guanine 628.

Claim 8 requires cleavage between guanine 636 and adenine 637. Claim 7 excludes cleavage between adenine 637 and guanine 638.

These limitations can create infringement disputes because RNAi cleavage is an event-dependent biological characteristic. Sequence alignment alone may establish annealing, but cleavage-site claims may require experimental evidence, validated mapping, or technical admissions concerning the product's mechanism.

A product could potentially satisfy claim 1 without satisfying claims 7 or 8. Claims 7 and 8 should therefore be analyzed separately rather than treated as interchangeable descriptions of the same duplex.

What chemical modifications and conjugates are covered?

Claims 10-14 extend the claimed dsRNA to modified and conjugated forms.

Claim 11 identifies:

2'-O-methyl nucleotides;
a 5'-phosphorothioate group; and
terminal attachment to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

Claim 12 covers a broader set of modifications, including:

2'-deoxy-2'-fluoro nucleotides;
2'-deoxy nucleotides;
locked nucleotides;
abasic nucleotides;
2'-amino modifications;
2'-alkyl modifications;
morpholino nucleotides;
phosphoramidates; and
non-natural bases.

Claim 13 specifically requires at least one 2'-O-methyl nucleotide. Claim 14 covers conjugation to a ligand but does not identify a particular ligand.

These claims are important because therapeutic siRNAs generally use chemical modifications to improve nuclease stability, reduce innate immune activation, improve pharmacokinetics, or support targeted delivery. The claims are not limited to one modification pattern. A product with the required TTR sequence may fall within a dependent modification claim even if its formulation or delivery technology differs from the original disclosure.

The claims do not, however, independently claim every chemically modified TTR siRNA. The underlying sequence and claim 1 limitations remain required.

Does claim 15 create a potency requirement?

Claim 15 requires approximately 95% inhibition of TTR mRNA expression at a 10 nM concentration in HepG2 or Hep3B cells, measured by real-time PCR.

This is a functional limitation. It can strengthen the claim against weak or inactive sequence variants, but it also introduces proof issues:

the assay protocol must be comparable;
"about 95%" requires construction of an acceptable range;
HepG2 and Hep3B cell conditions can affect RNAi performance;
transfection reagent, exposure time, and normalization method may matter; and
real-time PCR results may vary by primer set and reference gene.

A commercial product does not necessarily need to satisfy claim 15 if infringement is asserted under claim 1 or another claim. Claim 15 narrows the claim set and should be treated as an additional fallback position.

What pharmaceutical compositions and methods are protected?

Claims 20 and 22 cover pharmaceutical compositions containing the claimed dsRNA and a pharmaceutically acceptable carrier. Claim 20 depends on claim 1, while claim 22 depends on claim 4.

The composition claims can reach a finished drug product if the active RNA sequence is within the claims. They do not require a specific carrier, lipid, buffer, particle size, encapsulation efficiency, or route of administration.

Claims 21 and 23 cover cell-based methods:

Contacting a cell with the claimed dsRNA.
Maintaining the cell long enough to degrade TTR mRNA.
Achieving inhibition of TTR gene expression.

These method claims are directed to ex vivo or in vitro activity as written. They do not expressly require treatment of a human or animal. Their commercial value is therefore different from a method-of-treatment claim. They may be relevant to manufacturing assays, research services, screening systems, and product characterization, but direct enforcement against clinical use depends on the asserted claim and the facts of the activity.

How does US 8,168,775 relate to patisiran?

Patisiran is an siRNA therapeutic directed at TTR and marketed by Alnylam Pharmaceuticals under the brand name Onpattro. It uses a lipid nanoparticle delivery system and is administered intravenously for hereditary transthyretin-mediated amyloidosis [2].

US 8,168,775 is technically relevant because it claims TTR-directed RNA duplexes, including exact sequence-defined embodiments and chemically modified variants. The patent should not be equated automatically with complete protection for the marketed product. Product-level freedom-to-operate analysis requires sequence confirmation, formulation review, patent-family mapping, prosecution-history analysis, and comparison with all relevant issued claims.

The patent's claims are directed primarily to the active RNA and its use in TTR inhibition. Separate patents may address:

lipid nanoparticle composition;
ionizable lipid chemistry;
particle formation;
dosing schedules;
administration protocols;
manufacturing processes;
stability;
combination therapy; and
specific clinical uses.

A product can therefore face multiple independent patent layers even if it avoids US 8,168,775.

What is the Orange Book and FDA status relevance?

Patisiran was approved by the FDA in 2018 under a new drug application for hereditary transthyretin-mediated amyloidosis [2]. It is a chemically synthesized oligonucleotide drug, not a monoclonal antibody or other biologic approved under a BLA.

The principal regulatory implications are:

a biosimilar pathway under section 351(k) is not the normal route for patisiran;
a follow-on entrant would face an abbreviated or full NDA strategy rather than a conventional biosimilar filing;
Orange Book patent listings, if applicable to the NDA, must be checked against the current FDA listing; and
FDA approval does not itself establish that every patent covering the active sequence or delivery technology is listed in the Orange Book.

The Orange Book is a regulatory patent-listing database, not a complete patent landscape. Platform patents, manufacturing patents, foreign patents, and patents not submitted for listing may remain commercially relevant [3].

When does US Patent 8,168,775 lose exclusivity?

The patent issued on May 1, 2012. Its effective expiration depends on the patent family's earliest effective nonprovisional filing date and any patent term adjustment or terminal disclaimer recorded by the USPTO [1].

The claims supplied do not establish the expiration date, patent term adjustment, terminal disclaimer status, or whether a later reexamination or post-grant proceeding affected the claims. Those dates must be taken from the USPTO Patent Center record and the patent's term information.

For commercial planning, the relevant date is the enforceable expiration of the issued patent, not the publication date, issue date, or expiration of a related continuation. Continuation patents can carry different claim scope and expiration consequences if terminal disclaimers apply.

What generic entry risks exist?

A conventional generic challenge to an siRNA product is more complex than a small-molecule ANDA challenge.

Potential entry paths include:

Entry strategy	Relevance
Sequence design-around	Use a different TTR guide sequence
Paragraph IV challenge	Assert invalidity, noninfringement, or unenforceability against listed patents
505(b)(2) NDA	Rely partly on FDA findings while addressing differences in formulation or delivery
Full NDA	Submit an independent clinical and nonclinical package
Research or diagnostic use	Avoid commercial therapeutic claims while testing TTR inhibition
Foreign launch	Operate in jurisdictions where corresponding rights have expired, lapsed, or were not granted

The most direct design-around is a different antisense sequence. That approach may avoid literal infringement of claim 1, but it can trigger separate patent families covering alternative TTR sequences or broader RNAi delivery technologies.

A Paragraph IV case would likely focus on:

anticipation by earlier TTR siRNA disclosures;
obviousness of selecting the claimed sequence;
written description and enablement for the sequence and functional limitations;
indefiniteness of "about 95%" and cleavage limitations;
claim construction of "comprising SEQ ID NO:170";
infringement by modified or overhanging duplexes; and
terminal disclaimer or patent-term issues.

How strong is the patent estate?

US 8,168,775 has high sequence specificity and moderate platform breadth.

Strength factor	Assessment
Sequence enforceability	Strong if the accused RNA contains the claimed guide sequence
Design-around resistance	Limited because alternative guide sequences may avoid claim 1
Formulation coverage	Moderate; carrier is broadly recited but lipid chemistry is not claimed specifically
Modification coverage	Broad within the claimed sequence framework
Functional claim proof	More difficult because assay and cleavage evidence may be disputed
Product relevance	Potentially material for TTR siRNA products using the claimed sequences
Biosimilar relevance	Low; patisiran is not a conventional biologic biosimilar case
Manufacturing barrier	Limited in the supplied claims; separate process patents may be more important
Geographic coverage	US-only for this patent; foreign counterparts require separate review

What licensing and litigation issues affect the patent?

Alnylam's TTR franchise has involved a broader intellectual-property position than one patent. Licensing and collaboration arrangements in RNA interference have historically affected rights relating to therapeutic siRNA, delivery systems, and particular targets. Those agreements can allocate field-of-use rights without changing the public claim text.

A litigation review should separate:

litigation involving US 8,168,775 itself;
litigation involving continuation or divisional patents;
disputes over lipid nanoparticle technology;
inventorship or ownership challenges;
patent settlements involving competing TTR products; and
contractual licenses that affect enforcement or sublicensing.

The supplied claims do not identify any litigation, settlement, assignment, license, terminal disclaimer, or post-grant proceeding. The patent number alone is not sufficient to attribute a specific dispute to this patent.

Key Takeaways

US 8,168,775 is principally a sequence patent for TTR-targeting dsRNA.
Claim 1 requires an antisense strand comprising SEQ ID NO:170 and 19- to 24-nucleotide strands.
Claims 2-4 cover three specified duplexes, with claims 22 and 23 focused on the duplex of claim 4.
Claims 7-9 and 16 define specific TTR mRNA binding and cleavage characteristics.
Claims 10-14 extend coverage to modified and ligand-conjugated versions.
Claims 20-23 cover pharmaceutical compositions and cell-based TTR inhibition methods.
The patent may be relevant to patisiran, but product coverage cannot be determined from the claim text alone.
Alternative TTR guide sequences are the clearest design-around route, although other patent families may apply.
Biosimilar risk is limited because patisiran is an oligonucleotide drug approved under an NDA, not a conventional biologic approved under a BLA.
Expiration and enforceability require the USPTO patent-term, prosecution, assignment, and post-grant records.

FAQs

Does US 8,168,775 cover all TTR siRNA drugs?

No. The claims require defined sequence features, particularly antisense SEQ ID NO:170 or narrower listed duplexes. TTR siRNAs using unrelated guide sequences may fall outside these claims.

Does a lipid nanoparticle avoid infringement of US 8,168,775?

No. The claims focus on the dsRNA sequence and related compositions. Changing the delivery vehicle does not avoid a composition claim if the active dsRNA still satisfies the claim limitations.

Are GalNAc-conjugated TTR siRNAs covered?

They may be covered if the conjugated siRNA contains the required antisense sequence and satisfies the other limitations. Claim 14 recites a ligand conjugate, but the patent does not limit that claim to GalNAc.

Can an RNAi competitor challenge this patent through Paragraph IV?

Potentially, if the patent or a related patent is listed in the Orange Book for the relevant reference product and the entrant files an ANDA with a Paragraph IV certification. The regulatory pathway depends on the product and listed patent status.

Is the patent relevant to eplontersen or vutrisiran?

It may be relevant only if those products contain a claimed sequence or otherwise satisfy an issued claim. TTR target identity alone does not establish infringement.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,168,775, compositions and methods for inhibiting expression of transthyretin.
U.S. Food and Drug Administration. (2018). FDA approves first-of-its-kind targeted RNA-based treatment for rare disease.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2937418	⤷ Start Trial	122018000133	Germany	⤷ Start Trial
European Patent Office	2937418	⤷ Start Trial	300965	Netherlands	⤷ Start Trial
European Patent Office	2937418	⤷ Start Trial	PA2019501	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,168,775

Which drugs does patent 8,168,775 protect, and when does it expire?

Summary for Patent: 8,168,775